PF-03084014

Phase 2Small molecule

Pfizer

PF-03084014 is one of 149 small molecule programs targeting Leukemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

148

Competitors

Pipeline

Status by Indication[3][1]

Indication

LeukemiaActive, not recruiting

Triple-Negative Breast CancerActive, not recruiting

FibromatosisActive, not recruiting

Pancreatic AdenocarcinomaActive, not recruiting

Breast CancerActive, not recruiting

LeukemiaPhase 1

Active, not recruiting

Triple-Negative Breast CancerPhase 2

Active, not recruiting

FibromatosisPhase 2

Active, not recruiting

Pancreatic AdenocarcinomaPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

PF-03084014

Pfizer

Phase 2

2 2

Zolymbus

AbbVie

Preclinical

1 3

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 4

Zinecard

CChildren's Oncology Group

Preclinical

2 5

Avastin

Roche

Preclinical

4 6

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

3 7

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Preclinical

1 8

Naltrexone/bupropion

Novo Nordisk

Preclinical

1 9

Iniparib

Sanofi

Preclinical

6 10

Gadolinium-Chelate

MM.D. Anderson Cancer Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer2 trials

A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations

Terminated· Pfizer logo

Pfizer·Phase 2·NCT02299635·19 enrolled

A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer

Terminated· Pfizer logo

Pfizer·Phase 1·NCT01876251·30 enrolled

Pancreatic Adenocarcinoma1 trial

Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies

Terminated· Pfizer logo

Pfizer·Phase 2·NCT02109445·3 enrolled

Leukemia1 trial

A Trial In Patients With Advanced Cancer And Leukemia

Completed· Pfizer logo

Pfizer·Phase 1·NCT00878189·72 enrolled

Fibromatosis1 trial

Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01981551·17 enrolled

Triple-Negative Breast Cancer1 trial

Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer

Withdrawn·JJules Bordet Institute·Phase 2·NCT02338531

2 more indications

Patients With Advanced Solid Tumors1 trial

A Study Of PF-03084014 In Japanese Patients With Advanced Solid Tumors

Withdrawn· Pfizer logo

Pfizer·Phase 1·NCT02462707

Solid Tumor Malignancies1 trial

Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies

No longer available·UUniversity of Colorado, Denver··NCT02955446

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for PF-03084014. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PF-03084014 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PF-03084014. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Pfizer

PF-03084014

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer2 trials

Pancreatic Adenocarcinoma1 trial

Leukemia1 trial

Fibromatosis1 trial

Triple-Negative Breast Cancer1 trial

Patients With Advanced Solid Tumors1 trial

Solid Tumor Malignancies1 trial

References

Drug Info

Quick Facts

Related News